Drug Discovery
ByDo Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access and Market Expansion?
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning Point for Vanda Pharmaceuticals?
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s Disease Agitation Treatment?
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Can Dual Regulatory Approvals Position UltraGreen.ai as a Regional Leader in Fluorescence-Guided and AI-Enabled Surgery in Southeast Asia?
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
